Praluent Job - truth please

Quote
OK - there's a lot of opinions here. As a current employee in the cardio unit, I'll share my thoughts:
  • Continuity - REGN is unique from many biotechs in that its core leadership (CEO and CMO) has not changed in 30 years. Len Schleifer and George Yancopulous (sp) started the company in 1988.
  • Culture - oooh, REGN is, on paper, a small biotech company. On the Eylea or Dupixent teams, you've experienced more of that. Here, working across the Alliance with Sanofi where 1) we don't have leverage 2) nothing matters, since we don't make money 3) until recently, SNFI reps outnumbered us, and 4) SNFI reps mostly have no biotech experience - we feel like a Big Pharma company.
  • Praluent: Works better than advertised, and we should have outcomes for not just morbidity, but mortality that separates us from Repatha in next 12 months. It's one of the best drugs you can sell, and our "splash zone" is huge - e.g. patients who've had a cardiac event and re: statin - can't tolerate, or it's not enough. That's like 8-12MM patients in the U.S.
  • Amgen has competed well against upstarts like REGN. They do things that are very different than us, probably illegal, and yet effective. It's not clear if we can beat AMGN, who will fight "dirty". Our approach is the high road (better research, not hiking prices, etc.).
  • At REGN: R&D > Commercial. The good news: the R&D is impressive - proprietary fully human MAb technology end-to-end... if you have a disease with 1-2 well-characterized protein targets, we can probably build a biologic to beat it. The rock stars at REGN wear white lab coats, and that floats the stock price. Bad News: in the Commercial world - Field has no leverage against say, asinine expense reporting requirements, or HR (you get 18 days PTO, but NO sick days!).
  • You have to make your decision on your priorities. REGN is a great place to make a career. But if you want to make a pile of $$$ quickly, and move on - the entire organization does not look at the world like that. For example - the REGN oncology franchise was so promising that SNFI committed to $2B up front. So this is a place to be for the long term.
 












The truth about CV Medical Specialist positions:

No real leadership
No samples
No budget
No sick days
No communication
No real FAS coverage
No new marketing materials
No new marketing strategies
No better formulary for most
No new contracting with SP
No commitment to brand
Worthless stock options
Completely unrealistic goals
Completely dysfunctional copromote
SP reporting is a complete crapshoot
Reporting data is very questionable
Medicare patients CANNOT afford copays
Patients go into the donut hole very quickly
Office staff hate the difficult pull thru process
Cardiologists are apathetic to the PCSK9 class


Nothing has changed for the better here in 3 plus years. Do you really think things are going to improve anytime soon? If you think the outcomes trial is going to turn things around think again. Please convince me otherwise. We were sold a poop sandwich.
 






anonymous said:
The truth about CV Medical Specialist positions:

No real leadership
No samples
No budget
No sick days
No communication
No real FAS coverage
No new marketing materials
No new marketing strategies
No better formulary for most
No new contracting with SP
No commitment to brand
Worthless stock options
Completely unrealistic goals
Completely dysfunctional copromote
SP reporting is a complete crapshoot
Reporting data is very questionable
Medicare patients CANNOT afford copays
Patients go into the donut hole very quickly
Office staff hate the difficult pull thru process
Cardiologists are apathetic to the PCSK9 class


Nothing has changed for the better here in 3 plus years. Do you really think things are going to improve anytime soon? If you think the outcomes trial is going to turn things around think again. Please convince me otherwise. We were sold a poop sandwich.
Click to expand...
 






anonymous said:
The truth about CV Medical Specialist positions:

No real leadership
No samples
No budget
No sick days
No communication
No real FAS coverage
No new marketing materials
No new marketing strategies
No better formulary for most
No new contracting with SP
No commitment to brand
Worthless stock options
Completely unrealistic goals
Completely dysfunctional copromote
SP reporting is a complete crapshoot
Reporting data is very questionable
Medicare patients CANNOT afford copays
Patients go into the donut hole very quickly
Office staff hate the difficult pull thru process
Cardiologists are apathetic to the PCSK9 class


Nothing has changed for the better here in 3 plus years. Do you really think things are going to improve anytime soon? If you think the outcomes trial is going to turn things around think again. Please convince me otherwise. We were sold a poop sandwich.
Click to expand...


Very true with all of your points. I wish I could convince you (myself) otherwise but there is absolutely no positive indicators that things are getting better.
Hate to say it, but the outcome data ain’t that impressive.
 






I feel like shit ass. The points above are all true. We wait for outcome and publication but its probably not going to change a thing. Where are all the payors knocking down the door for our great 69% rebate? The offer has been extended to all of them.

We get news of a change in UM from a big part of our potential business-United Med D. Who the fuck cares? Its still $300-450 a month. Why the fuck doesnt anybody get it? The problem isn't the relaxed UM criteria, its the fucking price of the drug. Do you have to be and MBA to understand that? It's common sense, and it's also a shit load of greed.
 






Haha!!! yes, sad but very true. It's like living a nightmare.

Company wants class leadership. Hey I know, lets do the following:

Cut lunch money where we have the greatest chance to interact and sell
Cut samples when we are already being out-sampled
Cut speakers, and speaker program support
No publication despite all the grandstanding going on 6 months ago
Lose the MAJOR payers (CVS)

Yeah, that ought to get us there
 












anonymous said:
Haha!!! yes, sad but very true. It's like living a nightmare.

Company wants class leadership. Hey I know, lets do the following:

Cut lunch money where we have the greatest chance to interact and sell
Cut samples when we are already being out-sampled
Cut speakers, and speaker program support
No publication despite all the grandstanding going on 6 months ago
Lose the MAJOR payers (CVS)

Yeah, that ought to get us there
Click to expand...

Time to change your diaper baby
 












Alright, enough of the fuck. This company is just like all the other pharma pill companies. Huge admin. Lets talk about CV

No fucking outcomes. Despite the big hoopla back in February, nothing has happened. Zero. Shit. On top of that, we get one big payer win. Big fucking deal. Where are the payers who were supposed to be knocking down our door to get the big discount? Nice big talking there Phil Mealshit. Not only that, what happened to publication? Still fighting to get some fucking words in there to make Praluent look better than it really is? Hey I know, lets talk about that latex allergy thing! Yes! And now this just in: Praluent will get a standard review in late quarter of 2019. Nice fucking promises, big talking, and showboating. We were told expedited review, publication by end of summer '18, and "mortality data." Yeah, fucking right.

Lets cut samples. They don't correlate to sales, correct? Yeah, right.

Lets cut lunch money and speaker money. Nice. We'll show 'em.

Lets not ship all the Praluent that sits in the wherehouse because we've gone through our budget to mail it. Oh its too expensive to do that? Okay, enjoy your 45% class market share dick faces. Why don't you just lower the fucking price of the drug so we can get some more utilization?

Lets do this fucking expense report sign in shit thing. That shit and the degree to what they want does nothing to keep us at home doing administrative BS. But they dont care. They have their millions. Fuck.

Lets go to a week long meeting. We can do it during the peak of hurricane season. We dont really have material to fill up the week, so we'll put in lots of fillers. We can all act like fucking teenagers and have a "theme party." Yeah, that's fucking great. The place fuck stinks
 












anonymous said:
Alright, enough of the fuck. This company is just like all the other pharma pill companies. Huge admin. Lets talk about CV

No fucking outcomes. Despite the big hoopla back in February, nothing has happened. Zero. Shit. On top of that, we get one big payer win. Big fucking deal. Where are the payers who were supposed to be knocking down our door to get the big discount? Nice big talking there Phil Mealshit. Not only that, what happened to publication? Still fighting to get some fucking words in there to make Praluent look better than it really is? Hey I know, lets talk about that latex allergy thing! Yes! And now this just in: Praluent will get a standard review in late quarter of 2019. Nice fucking promises, big talking, and showboating. We were told expedited review, publication by end of summer '18, and "mortality data." Yeah, fucking right.

Lets cut samples. They don't correlate to sales, correct? Yeah, right.

Lets cut lunch money and speaker money. Nice. We'll show 'em.

Lets not ship all the Praluent that sits in the wherehouse because we've gone through our budget to mail it. Oh its too expensive to do that? Okay, enjoy your 45% class market share dick faces. Why don't you just lower the fucking price of the drug so we can get some more utilization?

Lets do this fucking expense report sign in shit thing. That shit and the degree to what they want does nothing to keep us at home doing administrative BS. But they dont care. They have their millions. Fuck.

Lets go to a week long meeting. We can do it during the peak of hurricane season. We dont really have material to fill up the week, so we'll put in lots of fillers. We can all act like fucking teenagers and have a "theme party." Yeah, that's fucking great. The place fuck stinks
Click to expand...
 






anonymous said:
Alright, enough of the fuck. This company is just like all the other pharma pill companies. Huge admin. Lets talk about CV

No fucking outcomes. Despite the big hoopla back in February, nothing has happened. Zero. Shit. On top of that, we get one big payer win. Big fucking deal. Where are the payers who were supposed to be knocking down our door to get the big discount? Nice big talking there Phil Mealshit. Not only that, what happened to publication? Still fighting to get some fucking words in there to make Praluent look better than it really is? Hey I know, lets talk about that latex allergy thing! Yes! And now this just in: Praluent will get a standard review in late quarter of 2019. Nice fucking promises, big talking, and showboating. We were told expedited review, publication by end of summer '18, and "mortality data." Yeah, fucking right.

Lets cut samples. They don't correlate to sales, correct? Yeah, right.

Lets cut lunch money and speaker money. Nice. We'll show 'em.

Lets not ship all the Praluent that sits in the wherehouse because we've gone through our budget to mail it. Oh its too expensive to do that? Okay, enjoy your 45% class market share dick faces. Why don't you just lower the fucking price of the drug so we can get some more utilization?

Lets do this fucking expense report sign in shit thing. That shit and the degree to what they want does nothing to keep us at home doing administrative BS. But they dont care. They have their millions. Fuck.

Lets go to a week long meeting. We can do it during the peak of hurricane season. We dont really have material to fill up the week, so we'll put in lots of fillers. We can all act like fucking teenagers and have a "theme party." Yeah, that's fucking great. The place fuck stinks
Click to expand...
 






anonymous said:
Alright, enough of the fuck. This company is just like all the other pharma pill companies. Huge admin. Lets talk about CV

No fucking outcomes. Despite the big hoopla back in February, nothing has happened. Zero. Shit. On top of that, we get one big payer win. Big fucking deal. Where are the payers who were supposed to be knocking down our door to get the big discount? Nice big talking there Phil Mealshit. Not only that, what happened to publication? Still fighting to get some fucking words in there to make Praluent look better than it really is? Hey I know, lets talk about that latex allergy thing! Yes! And now this just in: Praluent will get a standard review in late quarter of 2019. Nice fucking promises, big talking, and showboating. We were told expedited review, publication by end of summer '18, and "mortality data." Yeah, fucking right.

Lets cut samples. They don't correlate to sales, correct? Yeah, right.

Lets cut lunch money and speaker money. Nice. We'll show 'em.

Lets not ship all the Praluent that sits in the wherehouse because we've gone through our budget to mail it. Oh its too expensive to do that? Okay, enjoy your 45% class market share dick faces. Why don't you just lower the fucking price of the drug so we can get some more utilization?

Lets do this fucking expense report sign in shit thing. That shit and the degree to what they want does nothing to keep us at home doing administrative BS. But they dont care. They have their millions. Fuck.

Lets go to a week long meeting. We can do it during the peak of hurricane season. We dont really have material to fill up the week, so we'll put in lots of fillers. We can all act like fucking teenagers and have a "theme party." Yeah, that's fucking great. The place fuck stinks
Click to expand...
 












You will not hear this in Orlando :

- CLT pompous/elites attitude
- #metoomovement DAIICHI full background check
- 2019 commercial restructure
- Secret interviews. More Amgen folks
- Praluent sales lead the real story behind his absence at the POA
- Lack of respect and confidence for our sales force by Marion and her Amgen folks
- All being masked under a performance driven company to drive the stock up
- And finally the death of the Regeneron culture
 






You will not hear this in Orlando :

- CLT pompous/elites attitude

What do you expect they have millions in the bank. We deal with Medicare patients who can't afford drug and on fixed incomes.

- #metoomovement DAIICHI full background check

What the heck does that mean? Somebody hiding something in their background? Not a good thing in 2018 for sure.

- 2019 commercial restructure

What can they do differently? We use to have 4 fully resourced reps (2 CV, 2 PC) per territory and now we have 2 with little to promote with. Any decisions made in restructure will likely be by Sanofi

- Secret interviews. More Amgen folks

Maybe the new Amgen folks can talk leadership into commiting more resources to CV like Amgen does.

- Praluent sales lead the real story behind his absence at the POA

Is PM on his way out or already gone?

- Lack of respect and confidence for our sales force by Marion and her Amgen folks

Again, give us Amgen like resources (Samples, Budget, Marketing, Programs, DTC, PC Reps, FAS support) and we'll produce more.

- All being masked under a performance driven company to drive the stock up

Who doesn't want our stock to go up? CV Reps that have been here for 3 plus years and stock is still worthless. Soul crushing

- And finally the death of the Regeneron culture

Please define what Regeneron culture is anyway?
 












anonymous said:
The problem you have is that both drugs will only be niche drugs in the long run. This is what both studies showed.
Click to expand...

So what? Niche drug, hardly. Expensive yes but every FP and CV WANTS to use it but approval process is garbage. Want a real “niche” experience? Go talk to a rep in rare disease space. Where 1, maybe 2 scripts a quarter amounts to hundreds of thousands in revenue.
 






Top Bottom
Back
Quote